TFPI2 Antilichaam- / weefselfactorpathwayremmer 2

The extrinsic pathway of blood coagulation is initiated by contact of plasma factor VII with tissue factor, a cellular membrane glycoprotein that normally is segregated from the bloodstream but can be exposed after tissue injury or newly synthesized in endothelial cells or leukocytes after stimulation by endotoxin and cytokines. Inhibition of Factor VIIa tissue factor activity requires a plasma component (tissue factor pathway inhibitor (TFPI), lipoprotein-associated coagulation inhibitor (LACI) or extrinsic pathway inhibitor (EPI) ) and factor Xa. TFPI directly inhibits factor Xa, and, in an Xa-dependent fashion, also inhibits the Factor VIIa tissue factor catalytic complex. TFPI is a multivalent, Kunitz-type proteinase inhibitor that circulates in association with plasma lipoproteins VLDL, LDL, and HDL. TFPI-2 (also known as placental protein 5) is a related glycoprotein that was originally isolated from human placenta.

Immunohistochemistry (FFPE) : 1-2 µg/mL

P48307

Human

A portion of amino acids 100-235 from human Tissue factor pathway inhibitor 2 protein was used as the immunogen for the TFPI2 antibody.

TFPI2/13025

IHC-P

Protein G affinity

Purified

This TFPI2 antibody is available for research use only.

Aliquot the TFPI2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05% sodium azide

Optimal dilution of the TFPI2 antibody should be determined by the researcher.

Cell membrane, cytoplasm

IHC staining of FFPE human placental tissue with TFPI2 antibody (clone TFPI2/13025) . Inset: PBS used in place of primary Ab (secondary Ab negative control) . HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.